Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Adenosine Deaminase (ADA) has been used as a component of macrophage- serum-free media (SFM) to treat macrophages.

Adenosine deaminase has been used to pre-treat primary Kupffer cells.

Biochem/physiol Actions

Adenosine deaminase (ADA) is involved in the deamination of adenosine to inosine and 2′ deoxyadenosine to 2′-deoxyinosine.

Adenosine Deaminase (ADA) catalyzes the deamination of adenosine analogs to the corresponding inosine analogs. It is present in high levels in colorectal cancer and is a potential marker in tuberculous pleuriti. ADA deficiency affects T-and B-lymphocytes resulting in severe combined immunodeficiency (SCID) leading to lymphocytopenia.

General description

Adenosine Deaminase (ADA) is present majorly in the proximal small intestine and the duodenum. It is also called Adenosine aminohydrolase. It is a zinc metalloenzyme and exists as a high (230−440 kDa) and low molecular weight (30−47 kDa) isoforms.

Adenosine deaminase (ADA) is a zinc metalloenzyme.

Other Notes

For life science research only. Not for use in diagnostic procedures.

Physical form

Solution in 50% glycerol (v/v), 10 mM potassium phosphate, pH approximately 6

Preparation Note

Storage conditions (working solution): ADA (all preparations) may be dialyzed, without loss of activity, at 2 to 8 °C against 20 mM phosphate buffer, pH 7. The dialyzed preparation is stable at -15 to -25 °C.

Quality

Contaminants: ﹤0.01% alkaline phosphatase, AMP-deaminase, guanase, and nucleoside phosphorylase each